Riesgo residual. Conclusiones
Ángel Cequier(Bellvitge University Hospital), José Luis Zamorano(Hospital Universitario Ramón y Cajal)
Cited by 0
Related Papers
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|European Heart Journal|2016|3.2k
Thrombin-Receptor Antagonist Vorapaxar in Acute Coronary Syndromes
|New England Journal of Medicine|2011|753
Assessment of gastrointestinal and cardiovascular risk in patients with osteoarthritis who require NSAIDs: the LOGICA study
|Annals of the Rheumatic Diseases|2010|112
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
|Revista Española de Cardiología (English Edition)|2017|105
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemia
|European Heart Journal Supplements|2016|101